Purpose: This study aimed to assess MET amplification among different cancers, association with clinical factors and genetic aberrations and targeted therapy response modifications.
Introduction
MET is a proto-oncogene that encodes a transmembrane receptor with intrinsic receptor tyrosine kinase (RTK) activity named c-MET. As with many other RTKs, c-MET is involved in various key processes in normal mammalian development, including cell growth, regeneration, and tissue homeostasis (1) . Deregulation of c-MET activity has been described as an important process for cancer initiation and progression, leading to well-known hallmarks of cancer: cell migration, survival, angiogenesis, and invasiveness (1, 2) .
Hepatocyte growth factor (HGF) is the natural ligand of c-MET and its autocrine or paracrine (by tumor surrounding stroma) secretion of HGF may lead to increased c-MET activity in some cancers (3) . Additional mechanisms of c-MET activation in cancer are receptor overexpression, gene mutation, and amplification (4) . HGF-dependent and independent activation of c-MET leads to constitutive increased intra-cellular signaling through well-known oncogenic cascades, culminating in tumor aggressiveness (1) . Indeed, upregulation of the c-MET pathway is currently associated with aggressive pathologic features, poor prognosis, and treatment resistance in different tumor types (5) (6) (7) .
Although c-MET overexpression is described as the most frequent mechanism of constitutive c-MET activation in human cancers (8) , MET gene amplification has also been reported in different tumors, including gastroesophageal cancers (GEC; refs. 7, 9), glioblastoma (10) , non-small cell lung cancer (NSCLC; ref. 11) , and colorectal cancer (12) . Moreover, MET amplification has been described as a negative prognostic factor in NSCLC and GEC (7, 13, 14) , and is associated with development of resistance to new RTK inhibitors (15) (16) (17) .
Numerous agents have shown promise as therapeutic inhibitors of the c-MET pathway. Although crizotinib and cabozantinib are multi-RTKs inhibitors with activity against c-MET that recently obtained FDA approval, most c-MET inhibitors are under development and available only in clinical trials (18, 19) . Antitumor activity of these agents has been quite variable, suggesting the need for putative biomarkers that could indicate MET dependency and, thus, a higher therapeutic index in selected patients. MET amplification has been hypothesized to indicate a subgroup of patients sensitive to c-MET inhibition, although data are still preliminary (7) . In addition, a current standardization of MET amplification detection and a more comprehensive description of its prevalence across tumor types are lacking.
Therefore, we evaluated MET gene amplification in patients with advanced cancers referred to our Phase I Clinical Trials Program and explored the relationship between MET amplification with other molecular alterations and demographic data. We also explored the outcomes of patients treated on phase I clinical trials based on MET amplification status.
Patients and Methods

Patients
Patients with advanced cancers referred to the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center (MD Anderson; Houston, TX) from May 2010 until November 2012 were reviewed for possible inclusion. At the beginning of this period, MET amplification test became available at MD Anderson. Eligibility criteria for this retrospective review were a histologic confirmation of advanced malignancy, and having a tumor sample tested for MET amplification. This study and all associated treatments were conducted in accordance with the guidelines of the MD Anderson Institutional Review Board.
Tissue samples and molecular analysis
MET amplification was investigated in archival formalinfixed, paraffin-embedded tissue blocks or material from fine needle aspiration biopsies obtained from diagnostic and/or therapeutic procedures. All histologies were centrally reviewed at MD Anderson. MET amplification was analyzed via FISH at MD Anderson (n ¼ 1,058) or Baylor's Cancer Genetic Laboratory (n ¼ 92). MET FISH analysis was ordered at the discretion of the attending physician, according to the availability of archival material and clinical judgment about utility of the test result for selection of a clinical trial. Copy numbers were expressed as gene copy number in relation to CEP7, a gene located near the centrosome of the same chromosome. MET was considered amplified when the MET:CEP7 signal ratio was 2.0 or when this ratio was < 2.0 but there were > 20 copies of MET signals in more than 10% of the tumor nuclei counted, according to the criteria established by MD Anderson Pathology Department based on prior studies (20, 21 ). Whenever patients were tested for additional genetic alterations at the discretion of responsible physician, information data were also obtained. Mutational analysis was performed in Clinical Laboratory Improvement Amendment-certified laboratories as part of a gene panel analysis or in a single test. PTEN expression was tested with IHC using the monoclonal mouse anti-human antibody clone 6H2.1 (Dako), and complete loss of staining was classified as PTEN loss.
Treatment and evaluation
Patients referred to the Phase I Clinic who met inclusion criteria were enrolled in clinical trials judged to be clinically appropriate. Therapeutic agents were categorized according to the pathways they were supposed to target into: MET, PIK/ Akt/mTOR, Ras/Raf/MEK, HER, vascular endothelial growth factor (VEGF), and KIT inhibitors and cytotoxic agents. In cases of combination treatments or multikinase inhibitors, all possible targets were accounted for analysis. Treatment continued until disease progression, withdrawal of consent by the patient, clinical judgment deeming the necessity of removing a patient from a clinical trial, or development of unacceptable toxicity or death. Clinical assessments were performed as prespecified in each protocol, typically before the initiation of therapy and then at a minimum at the
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beginning of each new treatment cycle. Treatment response was assessed using CT scans, MRI, and/or PET scans at baseline, before treatment initiation and every two cycles (6-8 weeks). All radiographs were read in the Department of Radiology at MD Anderson and were reviewed in the Department of Investigational Cancer Therapeutics tumor measurement clinic. Responses were categorized using RECIST on the basis of specific protocol requirements (22, 23) , and were reported as best response. Clinical benefit was defined as partial responses and/or stable disease lasting more than 6 months. If a patient was treated on more than one phase I trial, results from the protocol on which they achieved the best response were analyzed.
Statistical analysis
Statistical analysis was verified by our statistician (K. Hess). Patient characteristics, including demographics, tumor type, MET amplification status, and associated genomic abnormalities, were summarized using frequency distributions and percentages. Categorical variables were compared via c 2 and Fisher exact tests, whereas continuous variables were compared via Student t test. Overall survival (OS) was assessed using Kaplan-Meier curve analysis starting from the date of the first appointment in the Phase I Clinic with comparison by the log-rank test. All tests were two sided when appropriate and considered significant at < 0.05. Statistical analyses were performed using SAS version 9.3 (SAS Institute Inc.).
Results
Patients
Between May 2010 to November 2012, 3,607 patients were referred to the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center for consideration of treatment on a phase I protocol. Among these patients, 1,115 (31%) underwent MET amplification testing by FISH. According to the established criteria, 29 (2.6%) patients had MET amplification. Median age of MET-amplified patients at diagnosis was 55 years (range, 19-71 years), 12 (41%) were male and 24 (83%) were white. Stratification by MET amplification status resulted in no differences in demographic characteristics, including age, ethnicity, or gender (all P > 0.10, Table 1 ).
MET amplification prevalence
The copy number of the MET gene in relation to CEP7 ranged from 2.05 to 16.14 (median 3.48). Of note, 2 patients were considered positive because more than 10% of cancer cells had greater than 20 copies of the MET gene. Prevalence of MET amplification was 2.5% (16/653) in samples from primary tumors, compared with 2.8% (13/ 461) in samples from metastatic sites (P ¼ 0.67, Table 2 ). One patient tested negative both in primary and metastatic tissue. MET amplification was detected in 2 (15%) out of 13 patients with adrenocortical carcinoma, 4 (14%) out of 28 patients with renal cell cancer, 5 out of 77 (6%) patients with GECs, 3 (5%) out of 64 patients with breast cancer, 4 (4%) out of 110 patients with ovarian cancer, and 4 (2%) out of 208 patients with colorectal cancer. MET amplification was also detected in samples derived from biliary, bladder, lung, salivary gland, lung cancer and melanoma (Tables 1 and 4 ). The following tumor types had more than 20 patients tested and no MET amplification detected: uterine cervix (n ¼ 30), endometrial (n ¼ 25), head and neck squamous cell cancer (n ¼ 58), liver (n ¼ 21), pancreas (n ¼ 24), prostate (n ¼ 40), sarcoma (n ¼ 101), and thyroid (n ¼ 23).
Pathologic and molecular characteristics of patients
MET-amplified patients presented with more metastatic sites, compared with nonamplified patients (median 3 vs. 4, P ¼ 0.0005). Twenty-six (90%) of the 29 positive samples were derived from adenocarcinomas, whereas the remaining were from melanoma (n ¼ 2) and urothelial cancer (n ¼ 1). Of note, all 119 samples from pure squamous cell tumors were negative for MET amplification. Histologic grade was available for 760 tumors. High-grade tumors were more frequent in MET-amplified [20/25 (80%)] compared with nonamplified patients [347/735 (47%), P ¼ 0.0033, Table 2 ). A more detailed analysis of tumor histology and grade by site is given in Supplementary Table S1. For grade and mutations, denominators are described (as patient evaluated for the characteristic) and we described row percentages. The most frequent concomitant genetic abnormality in the MET-amplified population was TP53 mutation in 7 out of 11 (64%) tested patients. MET-amplified tumors were associated with a higher prevalence of BRAF mutation (Table 2) . Of the 42 BRAF mutations detected in our cohort, 32 (76%) were V600E and 10 (24%) were non-V600E mutations and no association between type of BRAF mutation and MET amplification status was suggested. Detailed information about BRAF mutations by tumor site is given in Supplementary Table S2 . A concomitant MET mutation was absent in 9 patients with MET amplification tested for this abnormality.
Survival analysis
Median OS from first consult at our Phase I Clinic was 7.23 and 8.62 months, for MET amplification positive and negative patients. These results were not significantly different (P ¼ 0.29) and exhibited an HR of 1.12 (95% confidence intervals, 0.83-1.85; Fig. 1 ).
Outcomes on phase I protocols
We analyzed the outcomes of patients tested for MET amplification on phase I protocols. Among the 29 METamplified patients, 20 (69%) were enrolled on a phase I trial and were evaluable for response, compared with 648 out of 1,086 (60%) MET-nonamplified patients. Partial responses and stable disease were observed in 20% and 25% of METamplified patients, respectively, and in 9% and 47% of MET-nonamplified patients (Table 3) . Among the 7 METamplified patients treated on a c-MET inhibitor trial, 2 had stable disease, whereas the remaining 5 patients had progressive disease as their best response ( Table 3 ). All of the c-MET inhibitors used for these patients were tyrosine kinase inhibitors with anti-MET activity. On the other hand, of the 134 MET-nonamplified patients, 14 (10%) had a partial response and 48 (36%) had stable disease while being treated on a c-MET inhibitor protocol. Although responses rates were numerically better for MET-nonamplified patients, this difference did not reach statistical significance (P ¼ 0.86, Table 3 ). We further analyzed outcomes from MET-amplified patients according to the mechanism of action of the agents included on the phase I protocol. Three out of 6 (50%) patients presented with a partial response or stable disease lasting more than 6 months on a protocol that included a VEGF inhibitor and 3 out 8 (37.5%) treated on protocols that included an inhibitor of the PI3K pathway (in this case all of them were allosteric mTOR inhibitors, Table  4 ). Because of the low numbers of patients in this study, differences in outcomes according to drug targets were not significant within MET-amplified patient groups (Table 3) .
Discussion
MET amplification was detected in 2.5% of 1,115 patients with advanced solid cancers in different sites. The prevalence was highest in renal cell (14%) and adrenocortical tumors (15%), although other tumor types also exhibited non-trivial frequencies: gastroesophageal (6%), breast (5%), and ovarian cancers (4%). These results represent the largest number of solid tumors tested at the same cancer center to our knowledge. Series concentrated in a single tumor types reported MET amplification in 11% of papillary subtype of renal cancer (24), 2% to 7% of gastroesophageal tumors (7, 9, 25) , and 2.5% of ovarian cancers (26) . Very scarce data are available about MET amplification in many tumors, including breast and adrenal cancers. Adenocarcinomas were associated more with MET amplification than squamous cell tumors, a finding that has been previously observed in gastroesophageal tumors. In this setting, MET amplification has been reported in only 1% of esophageal squamous cell carcinoma, whereas it ranges from 2% to 10% in adenocarcinomas (7, 27, 28) .
In our series, MET-amplified tumors were associated with a higher histologic grade and development of more metastatic sites. Previous studies have already described the association between c-MET activation, either as protein overexpression or MET genetic abnormalities, with more aggressive phenotypes in prostate (29) , breast (30), gastroesophageal (7), lung (31) , and renal (32) cancers. Our results are in agreement with these findings. It is well recognized that c-MET activity is required for cell survival and long-distance migration during embryogenesis (33) . In preclinical models, induction of invasion in human carcinoma cells is mediated by c-MET activation through HGF binding (34) . We can speculate that MET amplification might confer a higher metastatic potential for cancer cells and, thus, development of more metastatic sites could result from this altered pathway.
In addition, if MET amplification is also related to a cancer cell survival advantage, it is likely to be more frequent in metastatic sites. A previous study demonstrated that MET-activating mutations were clonally selected during the development of metastasis in head and neck cancer, increasing their frequency of metastatic sites (35) . In agreement, studies in colorectal cancer confirmed that MET amplification was indeed more frequent in liver metastasis (21, 36) . In contrast, we detected only a slightly elevated frequency of MET amplification in metastatic tissues, which could be related to selection bias of our patient population, which included only tumors that progressed to advanced stages. Because we did not include primary tumors that remained localized, we cannot exclude the possibility that MET amplification was present as an early event in our MET-amplified samples that led to the development of metastasis.
The more aggressive biologic characteristic of MET-positive tumors is also reflected in the inferior survival outcomes found in many prior studies (5-7). We were not able to detect a statistically significant worse OS among METamplified patients, despite a more aggressive histologic grade and the presence of more metastatic sites. Lee and colleagues also reported that there was no impact on survival associated with c-MET overexpression in liver cancer (37) . It is important to note that different methods for evaluation of c-MET alterations, such as protein overexpression, gene mutation, and amplification have been used in prior series. Currently, there are few data about the interplay of these alterations. In our series, we included only patients with advanced and refractory cancer, measuring survival from the first phase I consult. A very short survival was detected in these patients, and the inclusion of different tumor types may have confounded possible prognostic implications of MET amplification. On the basis of our results, it is also not possible to exclude MET amplification as having prognostic implications that are tissue dependent.
Considering the potential of c-MET as a therapeutic target, it is important to explore whether there are correlations between MET amplification and genetic alterations in different molecular pathways. Interestingly, we described an association of MET amplification with BRAF mutation and PTEN loss. Loss and gains of genomic copy numbers of MET were previously correlated with PTEN loss in an exploratory analysis of salivary gland tumors (38) and c-MET inhibition was shown to cooperate with PI3K inhibition in preclinical models (39) . In addition, c-MET activation is a well-described mechanism of resistance to BRAF inhibitors (40) . The biologic significance of BRAF mutation or PTEN loss in the context of MET-amplified tumors is not clear, but may be relevant for the development of targeted therapies, especially c-MET-blocking agents and/or drug combinations. In this setting, further genomic studies are needed to reinforce this association.
With regards to performance of patients enrolled on phase I trials, the response rate of the 20 MET-amplified patients on their best phase I trial (RR of 20%) compared favorably with MET-nonamplified patients (RR of 9%) and the general response rate reported for phase I trials of unselected patients, usually between 5% and 10% (41, 42) . Nevertheless, the majority of MET-amplified patients presented with progressive disease as their best response and experienced a short time to treatment failure compared with MET wild-type patients. Therefore, this finding prompted us to further investigate the specific type of drug that benefited MET-amplified patients the most. Although the small number of patients in our study precludes coming to definitive conclusions, we observed that most MET-amplified patients who did achieve clinical benefit participated in protocols with VEGF inhibitors and/or agents blocking the PIK3 pathway. Considering that c-MET activation is a potent inducer of endothelial cell growth and angiogenesis (1, 43) , our finding merits further investigation. The lack of clinical activity of treatment with c-MET inhibitors for the 7 MET-amplified patients reported here was disappointing. Results from prior trials detected early activity of these agents in patients selected by c-MET protein overexpression and MET amplification in GECs (7, 44) , MET germline mutations in papillary renal cell cancer (24) , and chromosome polyploidy in gastric cancer (45) . However, it is to be noted, for patients with NSCLC, both onartuzumab and tivantinib in combination with EGFR did not meet their endpoints in an unselected population. An exploratory analysis of the phase II trial of onartuzumab in NSCLC suggested that c-MET IHC positivity was the best predictor of response for this drug compared with mutational assessment, gene expression, and FISH analysis of MET (46) . The same study noted a trend toward an OS benefit with onartuzumab for patients with more than five copy numbers of MET per cell by FISH. In our study, some patients were treated during the dose-escalation phase of some c-MET-inhibiting agents and they might not have received adequate doses to inhibit the pathway. It is also important to note that patients received only tyrosine kinase inhibitors with activity against c-MET, which precludes suggestions for other classes of c-MET inhibitors. In addition, there may be a minimum threshold of the MET:CEP7 ratio that confers c-MET dependency and sensitivity to c-MET inhibitors, similar to what was described recently for HER-2 and trastuzumab in gastric cancer (47) . One caveat is that among 1,115 patients tested, we detected only 7 (0.6%) patients with MET amplification with a ratio above 5, most of them with gastrointestinal tumors. Taken together, our data suggest that an integrative approach for the identification of biomarkers of response to c-MET inhibitors, including MET protein expression and genomic analysis should be pursued in different tumors as part of future research.
Among the limitations of this study are the referral bias of patients with aggressive and refractory tumors to a phase I clinical trial and the absence of the evaluation of c-MET receptor expression levels, limiting our comparisons with previous studies. Another limitation was that the exact timing of all samples in the course of their prior therapies was not available, and, hence, we could evaluate the influence of prior systemic treatments upon MET amplification status. We also regret to report that due to the ongoing nature of phase I trials, we are not allowed to disclose the identity of some of the investigational agents used in this study. Despite these limitations, we described the prevalence of MET amplification in different solid tumors and found MET amplification to be associated with adenocarcinomas, high-grade tumors, and development of more metastatic sites. Considering that there was an association with BRAF mutation and PTEN loss in addition to a variable predictive value of MET amplification, further studies are necessary to define how to better target this population.
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